secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000926617-23-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health FY2022 revenue $8.2M (+20% YoY); Q4 cash burn $7.1M
-------------------------------------------------------------------------

- Full-year revenue $8.2M, up 20% from $6.8M; OvaSuite volume 21,423 units (+23% YoY).
- Gross margin improved to 53% (FY) vs 45% in 2021; Q4 gross margin 57% vs 55%.
- Cash and short-term investments $13.6M at year-end; 2023 cash utilization guided $16-19M.
- OvaWatch launched late 2022; March 2023 coverage secured from major national payer.
- EndoCheck (endometriosis blood test) development on track for 2023 launch target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/0000926617-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/awh-20230322x8k.htm
  HTML page:      https://secwatch.observer/filing/0000926617-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer